Table 1.
Baseline demographic characteristics of patients included in the studies
| Characteristic | SPRING-1 | SPRING-2 | SINGLE | FLAMINGO | ||||
|---|---|---|---|---|---|---|---|---|
| DTG (N = 51) | EFV (N = 50) | DTG (N = 411) | RAL (N = 411) | DTG (N = 414) | ATR (N = 419) | DTG (N = 242) | DRV (N = 242) | |
| Median age, years | 37 | 40 | 37 | 35 | 36 | 35 | 34 | 34 |
| Male | 45 (88) | 44 (88) | 348 (85) | 355 (86) | 347 (84) | 356 (85) | 211 (87) | 201 (83) |
| White | 38 (75) | 43 (86) | 346 (84) | 352 (86) | 284 (69) | 284 (68) | 173 (71) | 176 (73) |
| ABC/3TC NRTI background | 17 (33) | 16 (32) | 169 (41) | 164 (40) | 414 (100) | 0 | 79 (33) | 80 (33) |
| Hepatitis B and/or C | 4 (8) | 6 (12) | 49 (12) | 43 (10) | 28 (7) | 30 (7) | 26 (11) | 20 (8) |
All data are expressed as n (%) unless otherwise specified
ABC/3TC abacavir/lamivudine, ATR atripla, DRV darunavir, DTG dolutegravir, EFV efavirenz, NRTI nucleoside reverse transcriptase inhibitor, RAL raltegravir